Physician profile
Lu Dai
NPI 1790399731
$1,877.05
in general payments reported to CMS, 2019-2025
26 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $863 · 2023: $605 · 2024: $243 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.78 |
| Education | $292.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $249.83 | 2022-2023 | |
| Janssen Biotech, INC. | $233.30 | 2023-2024 | Imbruvica, Darzalex, Tecvayli |
| Seagen INC. | $155.52 | 2022-2023 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $149.47 | 2022-2025 | |
| Incyte Corporation | $136.65 | 2022-2024 | Monjuvi |
| Regeneron Pharmaceuticals, INC. | $116.21 | 2024 | |
| Glaxosmithkline, LLC. | $100.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.64 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $79.26 | 2022-2023 | Imbruvica |
| Amgen INC. | $71.51 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Lilly USA, LLC | $70.89 | 2022-2023 | Verzenio, Retevmo, Jaypirca |
| Aveo Pharmaceuticals, INC. | $55.73 | 2022-2023 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $45.68 | 2022 | |
| Abbvie INC. | $42.30 | 2022 | |
| Morphosys, US INC. | $39.60 | 2022-2023 | Monjuvi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $37.83 | 2022 | |
| Sobi, INC | $34.20 | 2025 | |
| Pfizer INC. | $31.90 | 2025 | |
| Karyopharm Therapeutics INC. | $28.31 | 2024 | Xpovio |
| Mirati Therapeutics, INC. | $24.26 | 2023 | Krazati |
| Pharmaessentia USA Corporation | $20.81 | 2023 | Besremi |
| Celgene Corporation | $15.81 | 2022 | |
| Deciphera Pharmaceuticals INC. | $15.17 | 2023 | Qinlock |
| Merck Sharp & Dohme LLC | $14.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2023 | Opdivo |
| Rigel Pharmaceuticals, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lu Dai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.